ESR1 and osteoporosis: The controls had a mean age of 67.8 years, and 72.7% had received osteoporosis treatment (prior to enrollment in the study) that did not include denosumab (but did include bisphosphonates [used more than 1 year before THR] and hormone replacement therapy or selective estrogen receptor modulators [SERMs; used more than 3 months before THR]).